Cargando…

Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence

With emerging information about the potential for morbidity and reduced life expectancy with long-term use of opioids, it is logical to evaluate nonopioid analgesic treatments to manage pain states. Combinations of drugs can provide additive and/or synergistic effects that can benefit the management...

Descripción completa

Detalles Bibliográficos
Autores principales: Edinoff, Amber N., Fort, Juliana M., Singh, Christina, Wagner, Sarah E., Rodriguez, Jessica R., Johnson, Catherine A., Cornett, Elyse M., Murnane, Kevin S., Kaye, Adam M., Kaye, Alan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150009/
https://www.ncbi.nlm.nih.gov/pubmed/35645354
http://dx.doi.org/10.3390/neurolint14020035
_version_ 1784717331101908992
author Edinoff, Amber N.
Fort, Juliana M.
Singh, Christina
Wagner, Sarah E.
Rodriguez, Jessica R.
Johnson, Catherine A.
Cornett, Elyse M.
Murnane, Kevin S.
Kaye, Adam M.
Kaye, Alan D.
author_facet Edinoff, Amber N.
Fort, Juliana M.
Singh, Christina
Wagner, Sarah E.
Rodriguez, Jessica R.
Johnson, Catherine A.
Cornett, Elyse M.
Murnane, Kevin S.
Kaye, Adam M.
Kaye, Alan D.
author_sort Edinoff, Amber N.
collection PubMed
description With emerging information about the potential for morbidity and reduced life expectancy with long-term use of opioids, it is logical to evaluate nonopioid analgesic treatments to manage pain states. Combinations of drugs can provide additive and/or synergistic effects that can benefit the management of pain states. In this regard, tetrahydrocannabinol (THC) and cannabidiol (CBD) modulate nociceptive signals and have been studied for chronic pain treatment. Psilocybin, commonly known as “magic mushrooms”, works at the serotonin receptor, 5-HT(2A). Psilocybin has been found in current studies to help with migraines since it has a tryptamine structure and works similarly to triptans. Psilocybin also has the potential for use in chronic pain treatment. However, the studies that have looked at alternative plant-based medications such as THC, CBD, and psilocybin have been small in terms of their sample size and may not consider the demographic or genetic differences in the population because of their small sample sizes. At present, it is unclear whether the effects reported in these studies translate to the general population or even are significant. In summary, additional studies are warranted to evaluate chronic pain management with alternative and combinations of medications in the treatment of chronic pain.
format Online
Article
Text
id pubmed-9150009
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91500092022-05-31 Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence Edinoff, Amber N. Fort, Juliana M. Singh, Christina Wagner, Sarah E. Rodriguez, Jessica R. Johnson, Catherine A. Cornett, Elyse M. Murnane, Kevin S. Kaye, Adam M. Kaye, Alan D. Neurol Int Review With emerging information about the potential for morbidity and reduced life expectancy with long-term use of opioids, it is logical to evaluate nonopioid analgesic treatments to manage pain states. Combinations of drugs can provide additive and/or synergistic effects that can benefit the management of pain states. In this regard, tetrahydrocannabinol (THC) and cannabidiol (CBD) modulate nociceptive signals and have been studied for chronic pain treatment. Psilocybin, commonly known as “magic mushrooms”, works at the serotonin receptor, 5-HT(2A). Psilocybin has been found in current studies to help with migraines since it has a tryptamine structure and works similarly to triptans. Psilocybin also has the potential for use in chronic pain treatment. However, the studies that have looked at alternative plant-based medications such as THC, CBD, and psilocybin have been small in terms of their sample size and may not consider the demographic or genetic differences in the population because of their small sample sizes. At present, it is unclear whether the effects reported in these studies translate to the general population or even are significant. In summary, additional studies are warranted to evaluate chronic pain management with alternative and combinations of medications in the treatment of chronic pain. MDPI 2022-05-18 /pmc/articles/PMC9150009/ /pubmed/35645354 http://dx.doi.org/10.3390/neurolint14020035 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Edinoff, Amber N.
Fort, Juliana M.
Singh, Christina
Wagner, Sarah E.
Rodriguez, Jessica R.
Johnson, Catherine A.
Cornett, Elyse M.
Murnane, Kevin S.
Kaye, Adam M.
Kaye, Alan D.
Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence
title Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence
title_full Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence
title_fullStr Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence
title_full_unstemmed Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence
title_short Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence
title_sort alternative options for complex, recurrent pain states using cannabinoids, psilocybin, and ketamine: a narrative review of clinical evidence
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150009/
https://www.ncbi.nlm.nih.gov/pubmed/35645354
http://dx.doi.org/10.3390/neurolint14020035
work_keys_str_mv AT edinoffambern alternativeoptionsforcomplexrecurrentpainstatesusingcannabinoidspsilocybinandketamineanarrativereviewofclinicalevidence
AT fortjulianam alternativeoptionsforcomplexrecurrentpainstatesusingcannabinoidspsilocybinandketamineanarrativereviewofclinicalevidence
AT singhchristina alternativeoptionsforcomplexrecurrentpainstatesusingcannabinoidspsilocybinandketamineanarrativereviewofclinicalevidence
AT wagnersarahe alternativeoptionsforcomplexrecurrentpainstatesusingcannabinoidspsilocybinandketamineanarrativereviewofclinicalevidence
AT rodriguezjessicar alternativeoptionsforcomplexrecurrentpainstatesusingcannabinoidspsilocybinandketamineanarrativereviewofclinicalevidence
AT johnsoncatherinea alternativeoptionsforcomplexrecurrentpainstatesusingcannabinoidspsilocybinandketamineanarrativereviewofclinicalevidence
AT cornettelysem alternativeoptionsforcomplexrecurrentpainstatesusingcannabinoidspsilocybinandketamineanarrativereviewofclinicalevidence
AT murnanekevins alternativeoptionsforcomplexrecurrentpainstatesusingcannabinoidspsilocybinandketamineanarrativereviewofclinicalevidence
AT kayeadamm alternativeoptionsforcomplexrecurrentpainstatesusingcannabinoidspsilocybinandketamineanarrativereviewofclinicalevidence
AT kayealand alternativeoptionsforcomplexrecurrentpainstatesusingcannabinoidspsilocybinandketamineanarrativereviewofclinicalevidence